pharma · Solid Tumor, Adult · Solid Tumor · CTMX
CytomX Therapeutics
CytomX Therapeutics patent portfolio — 62 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- South San Francisco, USA
- Employees
- 98
- Programs
- 8
- Drugs
- 0
- Patents
- 62
CytomX Therapeutics patents
62 pharmaceutical patents indexed for CytomX Therapeutics. 0 expire within 24 months.
CytomX Therapeutics has 62 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 9688748
Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
granted -
US 9644016
Soluble notch receptor proproteins and methods of use thereof
granted -
US 9562073
Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
granted -
US 9545442
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
granted -
US 9540440
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
granted -
US 9517276
Compositions and methods for conjugating activatable antibodies
granted -
US 9487590
Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
granted -
US 9453078
Modified antibody compositions, methods of making and using thereof
granted -
US 9127053
Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
granted -
US 9120853
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
granted -
US 8993266
Proproteins activatable interferon alpha
granted -
US 8563269
Modified antibody compositions, methods of making and using thereof
granted -
US 8513390
Modified antibody compositions, methods of making and using thereof
granted -
US 8399219
Protease activatable interferon alpha proprotein
granted
Frequently asked questions
How many patents does CytomX Therapeutics have?
62 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do CytomX Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.